First Turn Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

First Turn Management’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-315,563	Closed	-$5.88M	–	34
2026 Q1	$5.88M	Buy	315,563 +52,920	+20%	+$877K	0.66%	33
2025 Q4	$3.46M	Hold	262,643	–	–	0.4%	33
2025 Q3	$1.88M	Buy	+262,643	New	+$13.7M	0.28%	29
2025 Q2	–	Sell	-179,196	Closed	-$7M	–	39
2025 Q1	$7M	Buy	+179,196	New	+$7.72M	1.41%	32

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

First Turn Management's MLTX Position: Q2 2026 in Review

First Turn Management sold out of MoonLake Immunotherapeutics (MLTX) in Q2 2026, closing a stake of 315,563 shares — an estimated $5.88M sold.

First Turn Management first reported a position in MLTX in Q1 2025 and held it in 4 quarters. The position peaked at $7M in Q1 2025. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

First Turn Management reported no remaining MoonLake Immunotherapeutics position as of Q2 2026 after selling out during the quarter.
First Turn Management sold 315,563 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $5.88M.
First Turn Management first reported a position in MoonLake Immunotherapeutics in Q1 2025 and held it in 4 quarters.
First Turn Management's MoonLake Immunotherapeutics position peaked at $7M in Q1 2025.
173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on First Turn Management's 13F filing for Q2 2026, filed 14 Aug 2026.